A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Breast Cancer Res Treat
मुख्य लेखकों: Ma, Cynthia X., Suman, Vera J., Goetz, Matthew, Haluska, Paul, Moynihan, Timothy, Nanda, Rita, Olopade, Olufunmilayo, Pluard, Timothy, Guo, Zhanfang, Chen, Helen X., Erlichman, Charles, Ellis, Matthew J., Fleming, Gini F.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2013
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4517667/
https://ncbi.nlm.nih.gov/pubmed/23605083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2528-8
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन